CLINUVEL Sustains Profitability in H1 FY26 While Accelerating Growth Pipeline.
CLINUVEL Pharmaceuticals (ASX: CUV) reported a resilient performance for the first half of FY2026, maintaining profitability while increasing strategic investment. Revenue rose 4% to AU$36.9 million, supported by ongoing SCENESSE sales and special access programs. Profit after tax came in at AU$10.4 million, reflecting higher operating costs linked to clinical development, personnel expansion, and commercial build-out. The company ended the period with approximately AU$233 million in cash reserves and no debt, reinforcing its capacity to self-fund future growth.
SCENESSE continues to anchor recurring revenues in erythropoietic protoporphyria (EPP), with regulatory progress underway in additional markets. Meanwhile, vitiligo represents a major expansion opportunity, with Phase III CUV105 results anticipated in the second half of 2026 and CUV107 recruitment scheduled to commence. Management also outlined substantial U.S. commercial potential in vitiligo. Backed by a strong balance sheet, disciplined capital management, and a broad melanocortin pipeline, CLINUVEL remains focused on sustainable long-term value creation.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
CLINUVEL Sustains Profitability in H1 FY26 While Accelerating Growth Pipeline.
CLINUVEL Pharmaceuticals (ASX: CUV) reported a resilient performance for the first half of FY2026, maintaining profitability while increasing strategic investment. Revenue rose 4% to AU$36.9 million, supported by ongoing SCENESSE sales and special access programs. Profit after tax came in at AU$10.4 million, reflecting higher operating costs linked to clinical development, personnel expansion, and commercial build-out. The company ended the period with approximately AU$233 million in cash reserves and no debt, reinforcing its capacity to self-fund future growth.
SCENESSE continues to anchor recurring revenues in erythropoietic protoporphyria (EPP), with regulatory progress underway in additional markets. Meanwhile, vitiligo represents a major expansion opportunity, with Phase III CUV105 results anticipated in the second half of 2026 and CUV107 recruitment scheduled to commence. Management also outlined substantial U.S. commercial potential in vitiligo. Backed by a strong balance sheet, disciplined capital management, and a broad melanocortin pipeline, CLINUVEL remains focused on sustainable long-term value creation.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au